A nationwide Department of Veterans Affairs clinical trial is opening a new chapter in the search for improved treatment options for alcohol use disorder, launching one of the largest studies to date examining whether semaglutide, a medication widely prescribed for Type 2 diabetes and weight management, may also help Veterans reduce or stop harmful alcohol use.
The research initiative comes as alcohol use disorder continues to affect hundreds of thousands of former service members across the United States and remains one of the most common behavioral health conditions treated within the VA health care system. By evaluating a medication already approved for other medical conditions, researchers hope to determine whether it can become an additional evidence-based option for Veterans working toward long-term recovery.
According to the Department of Veterans Affairs, more than 400,000 Veterans nationwide have been diagnosed with alcohol use disorder. Public health estimates also indicate that nearly one in nine adults in the United States experiences the condition, underscoring its impact not only on individuals but also on families, employers and health care systems.
Alcohol use disorder is a chronic medical condition characterized by an impaired ability to control or stop drinking despite negative health, social or occupational consequences. The disorder has been associated with increased risks of liver disease, heart problems, depression, anxiety, certain cancers and accidental injuries. It can also complicate treatment for other medical conditions, making comprehensive care an important part of long-term recovery.
The new VA study focuses on semaglutide, a medication belonging to a class of drugs known as glucagon-like peptide-1, or GLP-1, receptor agonists. While these medications were originally developed to improve blood sugar control in people with diabetes and later became widely used in obesity treatment, researchers have increasingly explored their potential influence on the brain’s reward pathways.
Scientists believe GLP-1 medications may affect regions of the brain involved in motivation, cravings and reinforcement, raising the possibility that they could help reduce the urge to consume alcohol. Recent medical research has suggested that patients prescribed GLP-1 medications for diabetes experienced lower rates of alcohol use disorder and other substance use disorders than comparable patients receiving different diabetes therapies. Additional observational findings have linked GLP-1 treatment among individuals with existing substance use disorders to fewer emergency department visits, hospitalizations and other serious health complications.
Although those findings have generated significant scientific interest, researchers emphasize that observational studies cannot establish whether the medication itself directly improves alcohol use disorder. The newly announced VA clinical trial is designed to answer that question through a carefully controlled research process.
Known as the Cessation or Reduction of Alcohol Consumption in Veterans trial, the study plans to enroll more than 600 Veterans between the ages of 18 and 80 who have been diagnosed with moderate or severe alcohol use disorder. Participants will receive weekly injections of either semaglutide or an inactive placebo during a 24-week treatment period, followed by additional safety monitoring after treatment concludes.
Throughout the study, investigators will evaluate changes in alcohol consumption, overall physical health and quality of life. Researchers will compare outcomes between participants receiving semaglutide and those receiving the placebo to determine whether the medication provides measurable benefits beyond existing treatment approaches.
The trial will be conducted at 18 VA medical centers across the country, including the Portland VA Medical Center, providing Veterans throughout Oregon with a regional opportunity to participate. For Veterans living in Southern Oregon communities such as Grants Pass, Medford, Ashland, Klamath Falls and surrounding areas, the Portland facility offers an in-state location where eligible individuals may learn more about enrollment through their local VA providers or by contacting the participating medical center.
Health experts caution that while the research is promising, semaglutide has not been established as a standard treatment for alcohol use disorder. Participation in the clinical trial is voluntary, and researchers will closely monitor participants throughout the study to ensure patient safety while collecting reliable scientific data.
Medical professionals also stress that Veterans should not attempt to self-medicate with GLP-1 medications or discontinue existing treatment programs based on preliminary research. Alcohol use disorder is a complex medical condition that often requires individualized care, which may include counseling, behavioral therapy, peer support, medication-assisted treatment or a combination of services tailored to each patient’s needs.
The VA continues to encourage Veterans experiencing alcohol-related health concerns to seek care through qualified health professionals rather than attempting to manage the condition independently. Established treatments remain available throughout the VA health care system while researchers work to determine whether semaglutide can safely become another tool in the growing range of therapies available for recovery.
Recruitment for the national study has begun, marking an important step in advancing research aimed at improving treatment outcomes for Veterans. If successful, the trial could help reshape future approaches to alcohol use disorder by expanding available medical options and providing clinicians with additional evidence to guide patient care. For Veterans across Oregon, including those in Southern Oregon, the study represents an opportunity to contribute to research that may influence the future of addiction medicine while potentially benefiting generations of Veterans yet to come.